These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 22788793)

  • 1. Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites.
    Vidler LR; Brown N; Knapp S; Hoelder S
    J Med Chem; 2012 Sep; 55(17):7346-59. PubMed ID: 22788793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Druggability of methyl-lysine binding sites.
    Santiago C; Nguyen K; Schapira M
    J Comput Aided Mol Des; 2011 Dec; 25(12):1171-8. PubMed ID: 22146969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
    Lori L; Pasquo A; Lori C; Petrosino M; Chiaraluce R; Tallant C; Knapp S; Consalvi V
    PLoS One; 2016; 11(7):e0159180. PubMed ID: 27403962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands.
    Hewings DS; Wang M; Philpott M; Fedorov O; Uttarkar S; Filippakopoulos P; Picaud S; Vuppusetty C; Marsden B; Knapp S; Conway SJ; Heightman TD
    J Med Chem; 2011 Oct; 54(19):6761-70. PubMed ID: 21851057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors.
    Ember SW; Zhu JY; Olesen SH; Martin MP; Becker A; Berndt N; Georg GI; Schönbrunn E
    ACS Chem Biol; 2014 May; 9(5):1160-71. PubMed ID: 24568369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solution structure and acetyl-lysine binding activity of the GCN5 bromodomain.
    Hudson BP; Martinez-Yamout MA; Dyson HJ; Wright PE
    J Mol Biol; 2000 Dec; 304(3):355-70. PubMed ID: 11090279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecule inhibitors of bromodomain-acetyl-lysine interactions.
    Brand M; Measures AR; Wilson BG; Cortopassi WA; Alexander R; Höss M; Hewings DS; Rooney TP; Paton RS; Conway SJ
    ACS Chem Biol; 2015 Jan; 10(1):22-39. PubMed ID: 25549280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and acetyl-lysine recognition of the bromodomain.
    Mujtaba S; Zeng L; Zhou MM
    Oncogene; 2007 Aug; 26(37):5521-7. PubMed ID: 17694091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical profiling of histone binding selectivity of the yeast bromodomain family.
    Zhang Q; Chakravarty S; Ghersi D; Zeng L; Plotnikov AN; Sanchez R; Zhou MM
    PLoS One; 2010 Jan; 5(1):e8903. PubMed ID: 20126658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains.
    Martin MP; Olesen SH; Georg GI; Schönbrunn E
    ACS Chem Biol; 2013 Nov; 8(11):2360-5. PubMed ID: 24007471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting bromodomains: epigenetic readers of lysine acetylation.
    Filippakopoulos P; Knapp S
    Nat Rev Drug Discov; 2014 May; 13(5):337-56. PubMed ID: 24751816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of Atypical Acetyl-lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.
    Clegg MA; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Leveridge M; Lindon M; Liwicki GM; Michon AM; Molnar J; Rioja I; Soden PE; Theodoulou NH; Werner T; Tomkinson NCO; Prinjha RK; Humphreys PG
    J Med Chem; 2020 Jun; 63(11):5816-5840. PubMed ID: 32410449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Activity-Based Probe Targeting Non-Catalytic, Highly Conserved Amino Acid Residues within Bromodomains.
    D'Ascenzio M; Pugh KM; Konietzny R; Berridge G; Tallant C; Hashem S; Monteiro O; Thomas JR; Schirle M; Knapp S; Marsden B; Fedorov O; Bountra C; Kessler BM; Brennan PE
    Angew Chem Int Ed Engl; 2019 Jan; 58(4):1007-1012. PubMed ID: 30589164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
    Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
    J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery.
    Chung CW; Dean AW; Woolven JM; Bamborough P
    J Med Chem; 2012 Jan; 55(2):576-86. PubMed ID: 22136404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
    Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
    J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Subset of Human Bromodomains Recognizes Butyryllysine and Crotonyllysine Histone Peptide Modifications.
    Flynn EM; Huang OW; Poy F; Oppikofer M; Bellon SF; Tang Y; Cochran AG
    Structure; 2015 Oct; 23(10):1801-1814. PubMed ID: 26365797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
    Ferguson FM; Fedorov O; Chaikuad A; Philpott M; Muniz JR; Felletar I; von Delft F; Heightman T; Knapp S; Abell C; Ciulli A
    J Med Chem; 2013 Dec; 56(24):10183-7. PubMed ID: 24304323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.